Germany's Fresenius SE & Co. KGaA tapped Goldman Sachs to explore a potential sale of its blood transfusion business, Reuters reported, citing sources.

The company has approached potential suitors regarding a sale, two people told the newswire.

In February, Fresenius CEO Stephan Sturm said the company was exploring all options for the transfusion and cell therapy unit.

Fresenius and Goldman declined to comment, according to the report.